Apellis Pharmaceuticals Stock Market Value
| APLS Stock | USD 17.64 -0.08 -0.45% |
| Symbol | Apellis |
Earnings Share 0.18 | Revenue Per Share | Quarterly Revenue Growth -0.06 | Return On Assets | Return On Equity |
Comparing Apellis Pharmaceuticals' market price with book value reveals how market sentiment relates to accounting fundamentals. Apellis Pharmaceuticals' market capitalization is 2.25 B. The 5.94 P/B ratio shows Apellis Pharmaceuticals carries a substantial premium over its balance-sheet equity. Enterprise value stands at 2.21 B. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value.
Apellis Pharmaceuticals' value is shaped by fundamental inputs, whereas price is shaped by supply and demand dynamics. For Apellis Pharmaceuticals, key inputs include a P/B ratio of 5.94, a profit margin of 2.23%, ROE of 7.48%, and revenue of 1 B.
What-If Analysis
What-if analysis for Apellis Pharmaceuticals is essentially a historical sensitivity test that shows how changes in the investment horizon could have altered realized return, drawdown, and timing outcomes. This becomes more informative when investors use the backtest to challenge timing assumptions rather than to search for a perfect historical entry point.
| 12/27/2025 |
| 03/27/2026 |
Opening a 0.00 position in Apellis Pharmaceuticals on December 27, 2025 and holding to today would realize 0.00 in total gains. The outcome is a 0.0% return on investment in Apellis Pharmaceuticals overall over the 90 day interval. All values are computed from publicly available trading activity and price records. Apellis Pharmaceuticals is grouped with peers such as Catalyst Pharmaceuticals, Kiniksa Pharmaceuticals, Mineralys Therapeutics, Beam Therapeutics, Adaptive Biotechnologies, Scholar Rock, and Ideaya Biosciences based on business similarity. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and ... More
Apellis Pharmaceuticals Momentum Range Indicators Signals
The momentum profile for Apellis Pharmaceuticals describes how price movement distributes across upside and downside channels. The data captures price, volume, and timing inputs from exchange activity.
| Information Ratio | -0.11 | |||
| Maximum Drawdown | 25.67 | |||
| Value At Risk | -4.94 | |||
| Potential Upside | 4.12 |
Market Risk Indicators for Apellis Pharmaceuticals Snapshot
Risk measures here provide context on Apellis Pharmaceuticals' return distribution and drawdown behavior. The information is presented without directional commentary.| Risk Adjusted Performance | -0.1 | |||
| Jensen Alpha | -0.40 | |||
| Total Risk Alpha | -0.14 | |||
| Treynor Ratio | -0.66 |
Statistical evidence for mean reversion in Apellis Pharmaceuticals' can be observed through its tendency to revert after extreme valuations. Investors who believe in mean reversion view Apellis Pharmaceuticals' price extremes as temporary dislocations that may self-correct. Valuation-driven investors use mean reversion to time Apellis Pharmaceuticals' investments around historical valuation multiples. Historical data for Apellis Pharmaceuticals shows that extreme valuations have tended to normalize over multi-year periods.
Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | -0.1 | |||
| Market Risk Adjusted Performance | -0.65 | |||
| Mean Deviation | 2.36 | |||
| Coefficient Of Variation | -774.33 | |||
| Standard Deviation | 3.45 | |||
| Variance | 11.91 | |||
| Information Ratio | -0.11 | |||
| Jensen Alpha | -0.40 | |||
| Total Risk Alpha | -0.14 | |||
| Treynor Ratio | -0.66 | |||
| Maximum Drawdown | 25.67 | |||
| Value At Risk | -4.94 | |||
| Potential Upside | 4.12 | |||
| Skewness | -0.68 | |||
| Kurtosis | 5.16 |
Apellis Pharmaceuticals Backtested Returns
Apellis Pharmaceuticals demonstrates a low volatility profile under current market conditions. It records an Efficiency (Sharpe) Ratio of -0.15, marking performance variability over 3 months. We identified twenty-two technical indicators influencing the company's volatility profile. Please assess metrics such as mean deviation of 2.36, and risk-adjusted performance of -0.1 to confirm statistical stability. The company owns a Beta (Market Risk) of 0.69, which implies generally lower market sensitivity than the broad market. As returns on the market increase, Apellis Pharmaceuticals' returns are expected to increase less than the market. However, during a bear market, the loss from holding Apellis Pharmaceuticals is expected to be smaller as well. At this point, Apellis Pharmaceuticals has a negative expected return of -0.52%.
Auto-correlation | 0.42 |
Average predictability
The autocorrelation profile for Apellis Pharmaceuticals registers average predictability between the two measured intervals. When lagged price patterns show consistency, they can serve as a partial input for modeling Apellis Pharmaceuticals's near-term price behavior. A serial correlation of 0.42 indicates that just about 42.0% of current Apellis Pharmaceuticals price fluctuations can be explained by its historical price movements.
| Correlation Coefficient | 0.42 | |
| Spearman Rank Test | 0.4 | |
| Residual Average | 0.0 | |
| Price Variance | 3.01 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |